Outset Medical Stock (NASDAQ:OM)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$4.69

52W Range

$3.00 - $21.36

50D Avg

$4.31

200D Avg

$6.94

Market Cap

$85.64M

Avg Vol (3M)

$159.01K

Beta

1.94

Div Yield

-

OM Company Profile


Outset Medical, Inc. is a medical technology firm that specializes in developing hemodialysis systems. The company's primary product is the Tablo Hemodialysis System, a compact console designed to deliver dialysis treatment in various environments, including hospitals and patients' homes. This innovative system boasts integrated water purification, on-demand production of dialysate, and advanced software complete with connectivity features. Founded in 2003, the company initially operated under the name Home Dialysis Plus, Ltd. before rebranding to Outset Medical, Inc. in January 2015. Its corporate headquarters are located in San Jose, California.

Show More

Industry

Medical - Devices

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

354

IPO Date

Sep 15, 2020

Website

OM Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 25Dec 24Dec 23
Consumables Product$54.08M$51.15M$42.21M
Consoles Product$30.73M$29.83M$61.33M
Product$84.81M$80.98M$103.54M
Service And Other Revenue$34.67M$32.71M$26.84M

Fiscal year ends in Dec 25 | Currency in USD

OM Financial Summary


Dec 25Dec 24Dec 23
Revenue$119.48M$113.69M$130.38M
Operating Income$-66.09M$-113.38M$-169.77M
Net Income$-81.65M$-127.98M$-172.80M
EBITDA$-66.71M$-97.89M$-153.79M
Basic EPS$-5.37$-36.95$-52.27
Diluted EPS$-5.37$-36.95$-52.27

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts


Q1 26May 09, 26 | 12:00 AM
Q4 25Feb 11, 26 | 4:30 PM
Q3 25Nov 10, 25 | 4:30 PM

Peer Comparison


TickerCompany
SNWVSANUWAVE Health, Inc.
SIShoulder Innovations, Inc.
QTRXQuanterix Corporation
INGNInogen, Inc.
OMIOwens & Minor, Inc.
NNOXNano-X Imaging Ltd.
TNYATenaya Therapeutics, Inc.
HSDTSolana Company
VMDViemed Healthcare, Inc.
CATXPerspective Therapeutics, Inc.